Halozyme Therapeutics | HALO - 现金及等价物



金融业
股票价格
USD
资产
USD 2.67B
现金及等价物
USD 309.75M
销售成本
USD 108.75M
流动资产
USD 1B
流动负债
USD 363.21M
债务
USD 2.14B
EBIT
USD -61.77M
EBITDA
USD 219.57M
员工
350
EPS每股收益
USD 1.6
股本和储备
USD 219.64M
销售毛利
USD 297.47M
债务利息支出
USD 5.51M
贷款资金
USD 1.94B
市值
USD 9.93B
净收入
USD 150.05M
营业费用
USD 192.19M
营业利润
USD -61.77M
普通股股本
USD 118.52M
PE价格收益
11.35
税前利润
USD 180.33M
销售收入
USD 377M
销售和管理费用
USD 46.29M
股票
USD 155.47M
贸易债权人
USD 14.1M
应收帐款人
USD 457.99M


现金及等价物 更改 日
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amarin USD 131.06M 3.6M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Baxter International USD 2.02B 51M 2026-03
Cara Therapeutics USD 20.73M 684K 2025-12
Cytokinetics USD 129.84M 7.32M 2026-03
DBV Technologies USD 174.9M 54.3M 2026-06
Eli Lilly USD 5.28B 1.99B 2026-03
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Intrexon USD 9.34M 1.77M 2024-06
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
MannKind USD 52.83M 22.05M 2026-03
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Pfizer USD 1.7B 561M 2026-03
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
United Therapeutics USD 1.28B 277.4M 2026-03
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12